he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源URL
上一页:癫痫的治疗费用是多少?
下一页:隐源性癫痫死亡率减半
- 2022-05-04中国生酮饮食疗法专家共识概要解读
- 2022-04-25亡中后癫痫首选用药有哪些?解答亡中后癫痫的4大问题
- 2022-04-202013年国际抗癫痫联合会抗癫痫泻药使用指南
- 2021-12-20癫痫病治疗的最佳短时间
- 2021-10-20癫痫病治疗作法都有哪些
- 2021-10-20全国癫痫病治疗好公立医院
- 心理百科:春节期间小心疾病
- 北京癫痫手术费用
- 癫痫治疗障碍仍难以克服
- 上海率先探索异地就医门诊费直接结算
- 预测癫痫患者再入院风险
- FDA警告怀孕期间使用丙戊酸钠药物
- 癫痫猝死:凶手是谁?
- 20首款慢性肾脏病治疗药物Forxiga获得NICE推荐
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 控制癫痫患者再次抽搐,不包括可选药物?
- 北京哪家癫痫医院排名好,成本低
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 泡温泉时不能忽视的事情
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 羊角病能生孩子吗?
- 心率多少正常 如何保持正常心率不变
- 2016AAN:神经专家发表了有前途的专业见解
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 综述:癫痫持续状态诊治最新进展
- 特发性癫痫大发作药物治疗的首选
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 不注意这些问题,吃多少药都没用!
- 抗癫痫药物预防新发癫痫:任重而道远
- 什么是治疗癫痫 癫痫有这些偏方?
- 癫痫患者手术评估新型工具
- 英国公平竞争监管机构控诉辉瑞公司癫痫药品价格过高
- 樟脑丸成分 樟脑丸有哪些效用
- 癫痫病不能吃掉什么食物-
- 避免二次开颅手术创伤 精准微创毁坏斩断“传导带”破解难治性
- 癫痫病发病究竟是居然
- 天气越来越冷 抑郁症患者预防病情有妙招
- 成年中风的病因有哪些啊
- 大脑或存在两种短时记忆系统会
- 治疗癫痫的款项是多少
- 20131029养生堂:王文志说心脑血管疾病的预防
- 癫痫病吃什食物用处多
- 什么是用药难治性癫痫?要怎么治疗?
- 癫痫病吃什么可以依靠
- 羊癫疯发作的症状哮喘